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Despite the widespread use of platinum drugs in the treatment of colorectal cancer (CRC), due to the 
heavy side effects and to intrinsic or acquired Pt resistance, new and more efficient drugs are 
urgently needed. Starting from the encouraging results obtained for the complex PtI2(DACH), we 
summarise here our recent advances, reporting data on the synthesis, on the chemical and biological 
features of two oxaliplatin analogues i.e. PtBr2(DACH) and PtCl2(DACH). The comparative approach 
of these studies reveals how these analogues possess interesting and differential pharmacological 
properties as well as some peculiar features that may be conveniently exploited to shed light in the 
mechanistic aspects involved in the pharmacological action of the parent drug. Furthermore, these 
findings are suitable for the design of more effective Pt-based anticancer drugs to be used in CRC 
treatment. 
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Introduction 
Colorectal cancer (CRC) is one of the most common cause of death for cancer worldwide.1 
Chemotherapy for CRC mainly relies on fluoropyrimidine compounds combined with platinum 
drugs, mainly cisplatin and its analogues carboplatin and oxaliplatin, being this latter the leading Pt-
based drug for the treatment of this pathology.2 Oxaliplatin (Eloxatin™) is a third-generation 
platinum compound approved by United States Food and Drug Administration (FDA) on 2002 for 
the treatment of advanced CRC. To date thousands of patients worldwide have been treated with 
oxaliplatin, especially in combination with other drugs.3 Indeed, either the FOLFOX (5-FU, 
leucovorin, and oxaliplatin) or CapeOx (capecitabine and oxaliplatin) regimens are used most often.4 
Nevertheless, serious drawbacks, such as a high systemic toxicity and platinum resistance are, still 
nowadays, relevant problems causing in some cases treatment failure. In recent times, we started 
to reconsider more systematically a series of clinically established Pt-based drugs analogues with 
unconventional ligands. In this view, we published some papers dealing with the chemical and 
biological features of cisplatin analogues where, the chlorido ligands were replaced by iodide and 
bromide ones. Interestingly, these modification lead to a modulation of chemical and biological 
profiles that substantially differ from those of the parent complex.5 
In this frame, worthy of particular consideration is the ability of the iodide analogue of cisplatin - 
i.e. cis-PtI2(NH3)2 - to overcome platinum resistance in CRC cell lines. This finding prompted us to 
further expand the panel of this family of compounds with unconventional ligands and, in analogy 
with cis-PtI2(NH3)2 the iodide analogue of oxaliplatin i.e. {(1R,2R)-cyclohexane-1,2-
diamine}diiodidoplatinum(II), (PtI2(DACH) hereafter), where the oxalate ligand was replaced by 
iodides, was synthesized and characterized.6 
PtI2(DACH) shown to possess a number of peculiar chemical and biological features that make it 
particularly attractive. Despite its solution behavior is characterized by a classical hydrolysis profile 
with halide release, yet, is scarcely reactive toward model proteins being instead highly reactive 
toward DNA ss oligonucleotides. Notably, we found PtI2(DACH) capable to induce cytotoxicity 
effects almost superimposable with those of oxaliplatin in representative CRC cell lines being this 
latter feature accompanied to a higher proapoptotic effect than cisplatin and oxaliplatin.6 In light of 
these results, and in order to further expand the panel of oxaliplatin analogues, we decided to 
prepare and comparatively evaluate two other analogs of oxaliplatin bearing either chloride or 
bromide ligands in place of oxalate i.e. PtCl2(DACH) and PtBr2(DACH). 
Importantly, both these two oxaliplatin derivatives, have been previously synthesized and 
extensively investigated as prospective antineoplastic agents either in vitro and in vivo on leukemia, 
ovarian or sarcoma models; yet, no information are available in literature regarding their possible 
application in the treatment of colorectal cancer.7,8a 
It may be stressed that, the presence of chloride or bromide ligands may lead to a selective 
modulation of important properties of these compounds, such as log P value and kinetic of ligands 
release, leading to a different biological and pharmacological properties. Also, the comparative 
analysis allows to correlate relevant chemical features with biological and pharmacological effects, 
that, in turn, allows to gain insights for the design of more effective complexes for CRC treatment. 
 
 
 
 
 
 
 
3 
 
 
Materials and Methods 
Chemicals and reagents 
Chemicals have been purchased from Sigma-Aldrich and were used without further purification. 
Dodecameric oligonucleotide ODN2 (sequence CTACGGTTTCAC), lysozyme (HEWL) and RNase have 
also been purchased from Sigma-Aldrich. 
 
Chemistry 
Synthesis of PtCl2(DACH) and PtBr2(DACH) 
 
The two reported compounds were synthesized and purified according to literature procedures with 
slight modifications.8 
 
{(1R,2R)-cyclohexane-1,2-diamine}dichloridoplatinum(II). PtCl2(DACH) has been obtained starting 
from 99,7 mg of K2PtCl4 (2.4010-4 mol) solubilised in 1.5 mL di of milli-Q water. 1,2-
diaminocyclohexane (1R,2R)-(-), DACH (27.4 mg, 2.4210-4 mol) was then solubilised in 2 mL of milli-
Q water and the obtained solution slowly added to K2PtCl4 water solution. After further four hours 
of stirring precipitate appeared, and complete precipitation of yellow crystals of PtCl2(DACH) 
allowed over night at room temperature. The solid was then collected through vacuum filtration 
and washed with hot water and ice-cooled ethanol and ether. 88.36 mg of PtCl2(DACH) were 
obtained (yield 96 %). Complex was characterised through 1H-NMR and elemental analysis. 1HNMR 
(DMF-d7, 400.13 MHz, 298 K): 2.45 (t, J = 8 Hz, 2H); 2.21 (d, J = 12 Hz, 2H); 1.52 (m, 4H); 1.16 (m, 
2H). Elemental analysis of C, N and H [calculated C: 18.96%, H: 3.71%, N: 7.37%, experimental: C: 
18.84%, H: 3.66%, N: 7.30%]. 
 
{(1R,2R)-cyclohexane-1,2-diamine}dibromidoplatinum(II). For the synthesis of PtBr2(DACH), 99.9 
mg of K2PtCl4 (2.4110-4 mol), have been solubilised in 1.5 mL di of milli-Q water. A water solution 
(2 mL) of KBr (117.7 mg, 9.6410-4 mol) was added to K2PtCl4 and stirred (50° C) in the dark for five 
minutes until quantitative conversion of K2PtCl4 in K2PtBr4 was obtained. 1,2-diaminocyclohexane 
(1R,2R)-(-), DACH (27.2 mg, 2.4110-4 mol) was then solubilised in 2 mL of milli-Q water and the 
obtained solution slowly added to K2PtBr4 water solution. After further four hours of stirring 
precipitate appeared, and complete precipitation of yellow crystals of PtBr2(DACH) allowed over 
night at room temperature. The solid was then collected through vacuum filtration and washed with 
hot water and ice-cooled ethanol and ether. 79.27 mg of PtBr2(DACH) were obtained (yield 70 %). 
Complex was characterised through 1H-NMR and elemental analysis. 1HNMR (DMF-d7, 400.13 MHz, 
298 K): 2.50 (t, J = 8 Hz, 2H); 2.23 (d, J = 12 Hz, 2H); 1.56 (m, 4H); 1.15 (m, 2H). Elemental analysis of 
C, N and H [calculated C: 15.36%, H: 3.01%, N: 5.97%, experimental: C: 16.50%, H: 3.14%, N: 6.30%]. 
 
 
 
Figure 1. The two synthesized molecules. 
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Scheme 1. Synthetic route for compounds 1 and 2, respectively. 
 
 
 
Uv-Vis experiments 
Solution behavior of PtCl2(DACH) and PtBr2(DACH) was assessed by spectrophotometric 
experiments performed with a Varian Cary 50 Bio UV-Vis spectrophotometer in the same condition 
used in our previous works.5a, 6 
 
Log P value determination 
The octanol-water partition coefficients for PtCl2(DACH) and PtBr2(DACH) was determined by 
modification of reported shake-flask method as reported in our previous work.6 
 
ESI-MS experiments 
For comparative purposes ESI-MS spectra of the ODN2-complexes and protein-complexes mixtures 
were recorded as already reported in literature.5b, 6 
 
Cell culture 
Human colorectal cancer cell lines (HCT-116, HCT-8 and HT29) were cultured in RPMI-1640 medium 
(Euroclone; Milan, Italy), supplemented with 2% L-Glut and 10% fetal bovine serum (FBS) (complete 
medium). Human embryonic kidney HEK293 cell line was cultured in DMEM medium (Euroclone; 
Milan, Italy), supplemented with 2% L-Glut and 10% fetal bovine serum (FBS). 
 
Cell viability assay 
To evaluate the IC50 of each compound, cell viability was assessed through the Trypan Blue exclusion 
test (Sigma-Aldrich). Cells were seeded at 1x104/well in 96-well plates (Costar Corning) in complete 
medium and incubated for 24h before compound addiction. Following the addition, cells were 
further incubated for 24 hours. Cells were then harvested and counted by the Trypan Blue exclusion 
test using a hemocytometer. All experiments were performed in triplicate. The IC50 values were 
calculated for each cell line and data fitted using a Hill1-type equation by using Origin Software 
(Microcal Origin 8.0 software; OriginLab Corporation, Northampton, MA). 
 
Cell cycle analysis 
Cell cycle distribution was assessed by flow cytometry after staining the cells with propidium iodide 
(PI). Cells were seeded and treated generally with different compound at their IC50 for 24h as already 
described.6 
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Results and Discussion 
 
Synthesis and characterization of PtCl2(DACH) and PtBr2(DACH) 
The same synthetic route already exploited for the synthesis of PtI2(DACH), and based on 
modification of existing method6,9 was used, as reported in more detail in material and methods 
section. Both complexes were obtained in good yield and their purity assessed through CHN 
analysis, found to be higher than 95%. 
 
Log P value determination 
Octanol-water partition coefficient is an important parameter giving important information related 
with the bioavailability and tendency of a compound to cross cell membranes. Through the 
modification of the classical flask-method and as already reported in our previous works,5,7,10 in line 
with the expectation we have determined for PtCl2(DACH) and PtBr2(DACH) a value respectively of 
-0,47 and -0,16. For comparison purposes log P values for a few parent Pt complexes are also 
reported in table 2. 
Remarkably, in line with results obtained for cisplatin analogues,5b PtBr2(DACH) manifests a larger 
lipophilic character than oxaliplatin and in less extent than PtCl2(DACH), whereas shows a lower 
lipophilicity than PtI2(DACH). It is well conceivable that this difference may have some appreciable 
effect in terms of pharmacological activity. 
 
 
Compound Log P 
Cisplatin -2,40* 
Oxaliplatin -1,58** 
PtI2(DACH) 0,76** 
PtCl2(DACH) -0,47 
PtBr2(DACH) -0,16 
Table 1. Determination of Log P for compound PtCl2(DACH) and PtBr2(DACH) compared with their 
iodide analogues, cisplatin and oxaliplatin. * Ref. 5a; **Ref. 6. 
 
 
Solution behaviour 
The solution behaviour of PtCl2(DACH) and PtBr2(DACH) was studied spectrophotometrically under 
physiological-like conditions. Freshly prepared aqueous solutions of PtCl2(DACH) and PtBr2(DACH), 
in 50 mM phosphate buffer, at pH = 7.4, manifest a bands in the UV-visible region, located at 320 
nm, that allow the continuous monitoring of the solution behaviour of this platinum complex (Figure 
2). 
After dissolution of the selected compounds in the reference buffer, progressive spectral changes 
are observed, consisting in a decrease of the band centered at 330 nm and the appearance of a new 
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band around 280 nm, tentatively assigned to a d–d and a LMCT transition, respectively.5b These 
changes, probably are ascribed to the progressive release of the two halide ligands.5,6 
The nature of the process and its kinetics are similar to what observed in the case of oxaliplatin 
despite release of halides in the case of PtCl2(DACH) and PtBr2(DACH) appears to be slightly faster 
than in case of oxaliplatin and PtI2(DACH) (Figure 3, Table 2). 
 
 
 
Figure 2. Time course spectra of (a) PtCl2(DACH) and (b) PtBr2(DACH) 10-4 M in 50mM phosphate 
buffer recorded over 72 h, RT. 
 
 
a 
b 
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Figure 3. Experimental kinetic traces and calculated theoretical curve for the hydrolysis of the halido 
derivatives 1 (a) and 2 (b). kobs was calculated fitting with a single exponential function (pH 
value=7.4). 
 
 
Compound Kobs (s-1) t1/2 (min.) 
PtCl2(DACH) 1,89×10-5 611,3 
PtBr2(DACH) 2,14×10-5 538,4 
PtI2(DACH)* 9,75 x 10-6 1184,58 
Oxaliplatin* 6,32 x 10-6 1827,92 
Table 2. Spectrophotometric determination of Kobs and t1/2 for the hydrolysis reaction of 1 and 2 10-
4 M in phosphate buffer over 72h. *The Kobs reported have been previously determined in our 
laboratory.6 For oxaliplatin Kobs was found to be close to that reported in literature by other 
authors.11 
 
 
Interaction with model biomolecules, ESI-MS experiments 
To investigate the possible interactions occurring between chlorido and bromido oxaliplatin 
analogues and its potential biomolecular targets, the two complexes were incubated with two 
model proteins i.e. RNase (Figure 4) and hen egg white lysozyme (Figure S7) and possible adducts 
formation was investigated. These two proteins were chosen since their structures have been often 
used to characterize the interactions occurring between proteins and metallodrugs. These model 
proteins are well suitable for ESI-MS studies, offering a very important substrate for comparative 
mechanistic studies of metal-based drugs. We performed a few ESI-MS experiments where the 
selected complexes were incubated in 20 mM ammonium acetate buffer, pH = 6.8 for increasing 
time intervals, from 24 to 72 hours. 
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Figure 4. Deconvoluted ESI-MS spectra of RNase A in 20 mM ammonium acetate buffer, pH = 6.8 
incubated with PtBr2(DACH) after 24-72 h at 37 °C. The protein concentration was 10-4 M (with 
complex to protein molar ratio of 3:1). *The saline buffer can contain small amount of phosphoric 
acid or sulphuric acid that are responsible of the formation of undesired and isobaric adducts with 
Ribonuclease A (+98 m/z).12 
 
 
ESI-MS spectra recorded for RNase in presence of PtBr2(DACH) did not showed any signal 
attributable to the metallated protein. The same results were obtained also for PtCl2(DACH). This 
indicate that the two compounds are not able to bind this protein. 
Also in the case of the ESI-MS spectra recorded for Lysozyme in presence of PtBr2(DACH) or 
PtCl2(DACH) did not showed any signal attributable to the metallated protein. In a previous study, 
similar results were obtained for PtI2(DACH).6 Conversely, in other works, some of us have shown 
significant interactions between oxaliplatin and the two selected model proteins.13,14 We 
hypothesized that an explanation for this difference in behaviour could be due to the fact that 
coordination of oxaliplatin to lysozyme and RNase implies a multi-step reaction at the level of 
aspartate residues. This implies, at first a non-covalent coordination of oxaliplatin to the protein; 
then detachment of one oxygen atom of oxalate from Pt coordination with a ring-opening step 
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leading to monodentatate oxalate, with concomitant Pt coordination of the carboxylate group from 
an aspartate residue. Finally, the complete release of the oxalate ligand.9,10 
The replacement of the oxalate with the halide ligands could cause loss of the first non-covalent 
interaction, which could be an important step in the reactivity of oxaliplatin with these proteins. 
 
Binding with model oligonucleotide: ESI-MS experiments 
It is generally accepted that the distortion of DNA generated upon binding of cisplatin and oxaliplatin 
is largely responsible for their antitumor properties.2,15 
Subsequent drug activation via intracellular aquation reactions results in a variety of stable 
bifunctional DNA–platinum(II) adducts. 1,2-Intrastrand cross-links between two adjacent guanine 
bases d(GG) or between an adenine and a guanine residue d(AG) are primarily formed. The platinum 
centre of complexes, with a cis motif, preferentially coordinates to the N7 position of both adenine 
and guanine in the major groove of DNA.16 For these reasons we tested the binding properties of 
the three oxaliplatin analogues with a simplified oligonucleotide model bearing the characteristic 
GG motif. 
The selected complexes interact extensively with the tested oligonucleotide bearing the GG motif 
(ODN2) through a classical reaction pattern involving preferential release of halide ligands (Figure 
5).17 PtBr2(DACH), in this case, shows a greater reactivity compared to PtCl2(DACH) and PtI2(DACH), 
as highlights the ESI-MS spectrum in figure 5, in which the peak of native ODN2 completely 
disappeared after adduct formations. 
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Figure 5. Deconvoluted ESI-MS spectra of ODN2 in Milli-Q water incubated with PtCl2(DACH) and 
PtBr2(DACH) after 72 h at 37 °C. The oligonucleotide concentration was 10-4 M (with complex to 
oligonucleotide molar ratio of 2:1). 
 
  IC50 value (µM, mean ± SEM) 
Cell lines Cisplatin Oxaliplatin PtCl2(DACH) PtBr2(DACH) 
HCT-116 24.4 ±0.6 49.9 ± 1.9 9.86 ± 1.4 30.96 ± 0.8 
HT-29 16.7 ± 2.3 18.8 ±2.5 49.07 ± 1.1 66.75 ± 2.0 
HCT-8 9.2 ± 1.5 33.1 ± 0.6 30.83 ± 0.1 48.64 ± 0.1 
HEK293 91.41 ± 4.15 >200 194.86 ± 6.8 >200 
 
Table 3. IC50 (µM) of Cisplatin, Oxaliplatin, PtCl2(DACH) and PtBr2(DACH) in HCT-116, HT-29 and HCT-
8 CRC cell lines, as well as in an embryonic kidney cell line cell line (HEK 293). Cell viability was 
determined after 24 hours of treatment with the four different compounds (range 0-300 M), by 
the Trypan Blue exclusion test. IC50 values (means ± sem of three independent experiments) were 
calculated using the Origin Software (Microcal Origin 8.0 software; OriginLab Corporation, 
Northampton, MA) fitting experimental data with Hill1 type equation. 
 
 
Biological effects 
The cytotoxic effects of PtCl2(DACH) and PtBr2(DACH) were then investigated in three CRC cell lines 
(HCT-116, HCT-8 and HT-29) in comparison with cisplatin and oxaliplatin. A normal cell line (HEK 293 
cells) was also included. Cells were exposed to increasing concentrations of the drugs for 24 hours, 
and the respective IC50 concentrations were determined by the Trypan blue exclusion test. 
As reported in Table 3, PtBr2(DACH) and in particular PtCl2(DACH), in comparison to oxaliplatin 
shows a greater cytotoxic effect only on the cell line least sensitive to cisplatin (i.e. HCT-116) being 
less effective in the other cancer lines. 
The PtX2(DACH) series conserves appreciable cytotoxic properties and is roughly similar to 
oxaliplatin. This implies that replacement of oxalate with two halido ligands does not impair the 
cellular effects of this drug. Additionally, when evaluating the effects of all compounds on 
embryonic kidney cell line HEK293, we can assert that the cytotoxicity is overall similar and rather 
low, being the PtCl2(DACH) significantly less cytotoxic. 
Based on these results we studied the effects that PtCl2(DACH) and PtBr2(DACH) (tested at their 
respective IC50s) produce on HCT-116 cells, determining the distribution of the cells in the various 
phases of the cell cycle. These effects were measured in the absence or in the presence of the four 
compounds tested at their respective IC50s. Preliminary results evidenced that as already reported 
for cisplatin, oxaliplatin and its iodido analog,5a PtCl2(DACH) and PtBr2(DACH) caused a variation of cell 
cycle distribution of HCT-116 cells (Table 4 and Figure 6), with a block in G2/M phase. The same 
effect has been found also in HCT-8 cells (Figure 7 and Supplementary Table 1). 
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 G0/G1 (%) S (%) G2/M( %) 
Control 31.8±0.6 31.2 ± 0.9 37.02 ± 1.4 
PtCl2(DACH) 20.2 ± 2.7 29.5 ±6.1 50.2 ± 6.1 
PtBr2(DACH) 23.1 ± 3.4 20.4 ± 2.4 56.6 ± 4.1 
Table 4. Cell cycle distribution of HCT-116 cells after 24 hours of treatment with PtCl2(DACH) and 
PtBr2(DACH) at the IC50 values shown in Table 3. Data are means±sem of four independent 
experiments, and are expressed as percentage of cells in each phase of the cell cycle, determined 
by flow cytometry after staining the cells with propidium iodide (PI). 
 
Figure 6. Cell cycle distribution of HCT-116 cells after 24 hours of treatment with PtBr2(DACH) and 
PtCl2(DACH) at the IC50 values. Representative histograms of data reported in Table 4.  
 
 
Figure 7. Cell cycle distribution of HCT-8 cells after 24 hours of treatment with PtBr2(DACH) and 
PtCl2(DACH) at the IC50 values. Representative histograms of data reported in Supplementary Table 
1.  
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Conclusion 
Colorectal cancer is a global health problem being the fourth most common cause of death due to 
cancer worldwide. Oxaliplatin plays a key role in current CRC treatment but shows serious 
drawbacks, such as a high systemic toxicity and the frequent insurgence of Pt resistance.  
This work continues a research line started a few years ago that is based on the idea that small 
modifications in the scaffold of established anticancer Pt drugs may lead to significant and hopefully 
positive changes in their pharmacological profile with appreciable effects in the overall spectrum of 
anticancer actions and in the ability to overcome Pt resistance in CRC. The exchange of halide ligands 
(e.g. replacement of chloride with iodide in cisplatin) represents indeed a small structural change 
with a relevant chemical and biological impact. 
Specifically, we have prepared here two analogues of oxaliplatin, an established Pt drug, through 
incorporation of non-conventional halido ligands such as chloride and bromide. From the inspection 
of the solution behavior, we have observed a hydrolysis profiles similar to oxaliplatin, with a with a 
release of the halido ligand more faster for chloride than bromide or iodide.  
At variance from oxaliplatin and in line with PtI2(DACH), the selected compounds showed a scarce 
reactivity towards model proteins, while keeping affinity for a standard DNA oligo. These findings 
are considerably interesting, in fact, despite DNA is recognized as the main target for Pt-based 
anticancer agents, protein binding is nowadays considered a key aspect for the pharmacological 
profile. Interaction with aminoacidic residues of proteins may have a primary role in the 
pharmacokinetic and bioavailability of metal-based antineoplastic compounds. Also, the 
coordination of metal center to specific protein sites, may result in an inhibition and damage of 
enzymes, leading in turn to augmented side effects.18 Thus, the lack of reaction of the study 
compounds when reacted with model protein targets, and the concomitant conserved reactivity 
toward oligonucleotides may have important biological consequences. 
Furthermore, we have shown that CRC cells that were treated with PtCl2(DACH) and PtBr2(DACH) 
showed at 24 hours a clear spike in the G2/M fraction; the cytotoxic properties versus CRC cell lines 
of the two study compounds were roughly comparable to those of oxaliplatin. This implies that the 
presence of the oxalate ligand is not crucial for the anticancer activity of oxaliplatin and that the 
latter may be replaced by halido ligands with nearly full retention of the cytotoxic properties. Results 
collected indicated that treatments with PtCl2(DACH) and PtBr2(DACH) affect growth of human CRC 
cells and induced cell cycle arrest suggesting an induction of cellular apoptosis. 
Overall, a rather interesting picture emerges for this novel Pt drug that merits, in our opinion, a 
deeper and more extensive preclinical evaluation. 
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